All news

ORIC Maintained by Stifel -- Price Target Raised to

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

Stifel analyst Laura Prendergast maintained a "Buy" rating on ORIC Pharmaceuticals and raised the price target to

Read original source

ORIC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.